Navigation Links
inVentiv Selling Solutions Selected to Provide Sales Team for Cephalon Inc.
Date:3/6/2008

SOMERSET, N.J., March 6 /PRNewswire-FirstCall/ -- inVentiv Selling Solutions, a division of inVentiv Health (Nasdaq: VTIV) and the industry leader in outsourced sales teams to the pharmaceutical industry, announced today that it has signed a contract with Cephalon Inc. to provide a sales team to support Amrix, Cephalon's once-daily extended-release muscle relaxant. In connection with this deployment, the company will also provide a variety of complementary services to support the sales program.

In addition to representing Cephalon, inVentiv Selling Solutions will use the same sales team to detail other, yet-to-be-identified products in the primary care market.

"inVentiv has a relationship with Cephalon that spans several of our companies and divisions. We are thrilled to be expanding that relationship by providing a sales team to support Amrix," said Paul Mignon, President of inVentiv Selling Solutions. "We look forward to putting our experience and our therapeutic expertise to work on behalf of this important product."

"inVentiv has an impressive track record and they've demonstrated a great willingness to work with us to help us achieve our goals," said Michael S. Mulholland, Senior Vice President, U.S. Pharmaceutical Operations at Cephalon, Inc. "We are very pleased to be partnering with them on this initiative."

About Cephalon, Inc.

Founded in 1987, Cephalon, Inc. is an international biopharmaceutical company dedicated to the discovery, development and commercialization of innovative products in four core therapeutic areas: central nervous system, pain, oncology and addiction. A member of the Fortune 1000, Cephalon currently employs approximately 3,000 people in the United States and Europe. U.S. sites include the company's headquarters in Frazer, Pennsylvania, and offices, laboratories or manufacturing facilities in West Chester, Pennsylvania, Salt Lake City, Utah, and suburban Minneapolis, Minnesota. The company's European headquarters are located in Maisons-Alfort, France.

The company's proprietary products in the United States include: PROVIGIL(R) (modafinil) Tablets [C-IV], FENTORA(R) (fentanyl buccal tablet) [C-II], TRISENOX(R) (arsenic trioxide) injection, AMRIX(R) (cyclobenzaprine hydrochloride extended-release capsules), VIVITROL(R) (naltrexone for extended-release injectable suspension), GABITRIL(R) (tiagabine hydrochloride), NUVIGIL(TM) (armodafinil) Tablets [C-IV] and ACTIQ(R) (oral transmucosal fentanyl citrate) [C-II]. The company also markets numerous products internationally. Full prescribing information on its U.S. products is available at http://www.cephalon.com or by calling 1-800-896-5855.

About inVentiv Health

inVentiv Health, Inc. (Nasdaq: VTIV) is an insights-driven global healthcare leader that provides dynamic solutions to deliver customer and patient success. inVentiv delivers its customized clinical, sales, marketing and communications solutions through its four core business segments: inVentiv Clinical, inVentiv Communications, inVentiv Commercial, and inVentiv Patient Outcomes. inVentiv Health's client roster is comprised of more than 325 leading pharmaceutical, biotech, life sciences and healthcare payor companies, including all top 20 global pharmaceutical manufacturers. For more information, visit http://www.inventivhealth.com.

This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Such forward-looking statements involve known and unknown risks that may cause inVentiv Health's performance to differ materially. Such risks include, without limitation: changes in trends in the pharmaceutical industry or in pharmaceutical outsourcing; our ability to compete successfully with other services in the market; our ability to maintain large client contracts or to enter into new contracts; uncertainties related to future incentive payments; and, our ability to operate successfully in new lines of business. Readers of this press release are referred to documents filed from time to time by inVentiv Health Inc. with the Securities and Exchange Commission for further discussion of these and other factors.


'/>"/>
SOURCE inVentiv Health, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Related medicine news :

1. inVentiv Health to Present at the 20th Annual Bear Stearns Healthcare Conference
2. inVentiv Health to Announce Third Quarter Results and Conduct Conference Call on Wednesday, November 7, 2007
3. inVentiv Health Launches Fourth Business Segment: inVentiv Patient Outcomes
4. inVentiv Health to Present at the 2007 Credit Suisse Healthcare Conference
5. inVentiv Health Creates Client Development and Integration Team
6. inVentiv Health Provides Updated Information on December 11th Investor Day
7. inVentiv Health to Announce Fourth Quarter and Full Year 2007 Results and Conduct Conference Call on Thursday, February 28th
8. inVentiv Health Ranked #17 by Training Magazine in its 2008 List of Top 125 Training Companies
9. inVentiv Health Reports Record Financial Results for Fourth Quarter and Full Year 2007
10. Federal Trade Commission Attempts To Suppress Best-Selling Authors First Amendment Rights
11. FTC Attacks Infomercial Marketer to Silence Best-Selling Authors Weight-Loss Tips
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:10/13/2017)... ... October 13, 2017 , ... The American Board of ... its next President and Chief Executive Officer, succeeding Dr. James C. Puffer upon his ... July 1, 2018 until Dr. Puffer’s retirement at the end of 2018. Upon assuming ...
(Date:10/13/2017)... ... , ... Lori R. Somekh, founder of the Law Office of Somekh ... law and special needs planning attorneys. “Membership in ElderCounsel helps our office remain up ... network with elder law attorneys nationwide,” said Somekh. , ElderCounsel was ...
(Date:10/13/2017)... ... October 13, 2017 , ... Ellevate Network, the leading network for professional women, ... towards gender equality at their inaugural Summit in New York City in June. The ... social audience of over 3 million. To watch the Mobilize Women video, click ...
(Date:10/13/2017)... ... October 13, 2017 , ... ... Agile Software Development, has been awarded a contract by the Center for Medicare ... (BPA) aims to accelerate the enterprise use of Agile methodologies in a consistent ...
(Date:10/12/2017)... ... October 12, 2017 , ... CitiDent and San Francisco ... using cutting-edge Oventus O2Vent technology. As many as 18 million Americans are estimated ... in breathing. Oral appliances can offer significant relief to about 75 percent of ...
Breaking Medicine News(10 mins):
(Date:10/4/2017)... , Oct. 4, 2017 ... single-use, self-contained, illuminating medical devices, today announced regulatory ... Health Surveillance Agency (or Agência Nacional de Vigilância ... first single-use, cordless surgical retractor with integrated LED ... optimal access, illumination and exposure of a tissue ...
(Date:10/2/2017)... , Oct. 2, 2017  AllianceRx Walgreens Prime, ... formed by Walgreens and pharmacy benefit manager Prime Therapeutics ... new brand, which included the unveiling of new signage ... , as well as at a few other company-owned ... new brand to patients, some of whom will begin ...
(Date:9/28/2017)... , Sept. 28, 2017 Hill-Rom Holdings, ... 2017 earnings conference call and webcast on Friday, November ... a.m. (EDT) and ending at approximately 8:30 a.m. (CDT) ... discussing the company,s 2017 financial performance and guidance for ... opportunities, initiatives to enhance operational performance, and long-range financial ...
Breaking Medicine Technology: